Cambridge Healthtech Institute Inaugural Combination Cancer Immunotherapy

It is now established that most immune modulating antibody-based immunotherapies offer more benefit to the patient by being administered in combination with other traditional forms of cancer management or in tandem with other checkpoint inhibitors and/or co-stimulatory agonists. A wave of clinical trials is now underway to explore new combinations and how they should be dosed and sequenced for maximum efficacy.
“Combination Cancer Immunotherapy” seeks to advance this field by offering researchers and clinicians a forum in which to examine the treatment strategies that will be most effective as this field evolves. Presentations will explore how individual components are identified and developed for use in combinations, how to design combinations for maximum effect in specific tumor types and the conclusions that can be drawn from recent trials of common combination types. The meeting also will examine the best ways to combine new understandings of immunotherapy with new advances in biotherapeutic product formats – and then how to advance these programs through regulatory approval and into clinical application.
A companion conference earlier in the week, “Immunomodulatory Therapeutic Antibodies for Cancer”, will examine the discovery and development of the next wave of checkpoint regulators and co-stimulatory factors that will form the basis for many of the combination regimens that will be discussed at this meeting.
We invite proposals for the conference that offer new data, new approaches and novel science from industry scientists and academic research groups working to improve the efficacy and scope of cancer immunotherapy through combinations.